Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tandem Diabetes Care, Inc. (NASDAQ: TNDM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tandem Diabetes Care is a global insulin delivery and diabetes technology company whose common stock is registered under Section 12(b) of the Exchange Act and listed on the NASDAQ Global Market under the symbol TNDM.
Through this page, users can review current reports on Form 8-K that document material events such as quarterly earnings announcements, regulatory clearances, and board of director changes. Recent 8-K filings referenced by the company include reports on financial results for quarters ended during 2025 and the appointment of a new independent director to the board, along with related committee assignments and compensation details. Other 8-K filings describe FDA 510(k) clearance for the SteadiSet infusion set and similar operational milestones.
In addition to 8-Ks, Tandem Diabetes Care files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed information on its insulin delivery systems, financial condition, risk factors, and business strategy. These filings are important for understanding how the company’s pump portfolio, infusion sets, mobile applications, and cloud-based platforms contribute to its overall operations and financial results.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify information on revenue drivers, regulatory developments, and governance matters. The platform also surfaces insider transaction reports on Form 4 when available, allowing investors to monitor share transactions by directors and officers. Real-time updates from the SEC’s EDGAR system ensure that new Tandem Diabetes Care filings appear promptly, while AI-generated explanations make complex regulatory language more accessible.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos exercised restricted stock units and had shares withheld for taxes. On April 15, 2026, he converted 3,636 restricted stock units into an equal number of common shares at a $0.00 exercise price under a long-term incentive plan.
To cover tax withholding on the RSU vesting, 1,926 common shares were withheld by Tandem Diabetes Care Inc. at $20.66 per share, with no shares sold on the market. Following these transactions, he directly holds 25,772 shares of common stock and 18,181 restricted stock units.
Tandem Diabetes Care, Inc. is asking stockholders to approve a broad slate of governance, compensation and equity plan items at its 2026 virtual annual meeting on May 20, 2026. Investors will vote on electing nine directors for one-year terms and on a non-binding advisory approval of 2025 executive pay.
The company seeks approval to amend its 2023 Long-Term Incentive Plan to increase shares authorized for issuance by 3,260,000, supporting ongoing equity awards to employees, directors and other service providers. Stockholders are also asked to approve charter amendments aligning director removal rights with Delaware law and adding officer exculpation within newly expanded legal limits.
Other proposals include ratifying Ernst & Young LLP as independent auditor for 2026. The proxy highlights 2025 business results, including approximately $1.015 billion in worldwide sales and more than 126,000 annual pump shipments, and describes a pay-for-performance program where named executives earned 87% of target cash bonuses.
Tandem Diabetes Care is holding its 2026 Annual Meeting virtually on May 20, 2026 to vote on seven proposals, including election of nine directors, say-on-pay, an increase of 3,260,000 shares to the 2023 Long-Term Incentive Plan, certificate of incorporation amendments, and ratification of Ernst & Young LLP as auditor.
The Record Date shows 68,504,233 shares outstanding as of March 23, 2026. The company reports 2025 business highlights including $1.015 billion in worldwide sales, over 126,000 pump shipments, and several product and regulatory milestones.
The Vanguard Group filed Amendment No. 8 to a Schedule 13G/A for Tandem Diabetes Care, reporting 0 shares beneficially owned and 0% of the class as of the filing. The filing explains an internal realignment under SEC Release No. 34-39538 that caused certain subsidiaries or business divisions to report separately. The filing lists The Vanguard Group's address as 100 Vanguard Blvd., Malvern, PA and Tandem's principal executive office as 11075 Roselle Street, San Diego, CA. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/27/2026.
Tandem Diabetes Care EVP & Chief Commercial Officer Mark David Novara reported several equity transactions. He exercised 7,414 Restricted Stock Units into the same number of common shares at a $0.00 conversion price, reflecting RSU vesting under the company’s 2023 Long-Term Incentive Plan.
To cover taxes on this vesting, 5,540 shares of common stock were withheld by Tandem Diabetes Care Inc. at $21.59 per share; the footnotes clarify that no shares were sold for this tax-withholding disposition. Novara then executed a separate open‑market sale of 187 common shares at $23.05 per share on the following day.
After these transactions, he directly holds 37,656 shares of common stock. The filing notes that the open‑market sale was carried out under a Rule 10b5‑1 trading plan that Novara adopted on December 4, 2025, indicating the sale was pre‑scheduled rather than a discretionary trade.
Tandem Diabetes Care (TNDM) filing reports a proposed sale of 187 shares of Common Stock tied to Restricted Stock Units with an effective date of 03/15/2026. The filing also records a 10b5-1 sale of 2 shares of Common Stock executed on 03/05/2026 at $45.62.
The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, and the reporting individual is Mark Novara. This Form 144 is a routine notice of intended resale and an executed small 10b5-1 disposition.
Tandem Diabetes Care executive Mark David Novara, EVP & Chief Commercial Officer, sold 2 shares of the company’s common stock in an open-market transaction. The sale occurred at a price of $22.81 per share. After this small sale, he directly holds 35,969 shares of Tandem Diabetes Care common stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Novara adopted on December 4, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.
Tandem Diabetes Care completed a private offering of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The notes are senior unsecured, pay no regular interest, and mature on March 15, 2032, unless earlier converted, redeemed or repurchased.
Holders can convert under specified stock price and trading conditions before December 15, 2031, and at any time thereafter until shortly before maturity. The initial conversion rate is 27.0362 shares per $1,000 principal amount, implying a conversion price of about $36.99 per share, a premium of roughly 37.5% to the $26.90 share price on February 24, 2026.
Net proceeds were about $290.7 million, with $15.3 million used to purchase capped call transactions that are designed to reduce potential dilution or offset cash payments above principal on conversion. The remaining proceeds are earmarked for general corporate purposes, including possible acquisitions, investments, working capital, operating expenses and capital expenditure.